TRK-IN-34 is an orally active TRKand TRKC mutant kinase inhibitor, with IC50 values of 0.75 nM and 0.96 nM against TRKAG595R and TRKAG667C, respectively. TRK-IN-34 inhibits the kinase activities of TRKAG595R and TRKAG667C at the functional level. TRK-IN-34 inhibits the proliferation of TRKA-transfected cells, exerts tumor growth-inhibitory effects and achieves partial tumor regression in xenograft models. TRK-IN-34 can be used to study TRK inhibitor-resistant cancers driven by the TRKAG667C mutation[1].
Molekulargewicht:
420.36
CAS Nummer:
[2489327-91-3]
Formel:
C19H16F4N6O
Target-Kategorie:
Trk Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
